Skip to content

Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity

Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01203436
Acronym
STOP-ROP
Enrollment
649
Registered
2010-09-16
Start date
1994-02-28
Completion date
1999-03-31
Last updated
2015-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blindness, Infant, Low Birth Weight, Infant, Newborn, Infant, Premature, Infant, Small for Gestational Age, Retinopathy of Prematurity

Keywords

NICHD Neonatal Research Network, Very Low Birth Weight (VLBW), Extremely Low Birth Weight (ELBW), Prematurity

Brief summary

The purpose of this trial was to determine the efficacy and safety of supplemental therapeutic oxygen for infants with prethreshold retinopathy of prematurity (ROP) to reduce the probability of progression to threshold ROP and the need for peripheral retinal ablation.

Detailed description

Retinopathy of prematurity (ROP) is an abnormal growth of the blood vessels in the eye that occurs primarily in very premature infants. Eye development occurs normally in the womb; in infants born prematurely, however, the blood vessels must finish developing outside the protective environment of the uterus. Retinopathy of prematurity (also known as retrolental fibroplasia) is a leading cause of blindness and other vision impairments (myopia, strabismus, and amblyopia) in children, both in developed and developing countries. This study was a randomized trial comparing the effects of 2 oxygenation strategies on the progression of ROP. Infants with prethreshold ROP in at least one eye were eligible for the study. Enrolled infants were randomized to receive either conventional oxygenation at a pulse oximetry target of 89% to 94%, or supplemental oxygen to achieve a pulse oximetry target range of 96% to 99%. Infant were placed on continuous pulse oximetry monitoring and to maintain oxygen saturation, as much as possible, in the assigned target range.

Interventions

PROCEDURESupplemental Oxygen Management

Supplemental arm with pulse oximetry targeted at 96% to 99% saturation, for at least 2 weeks, and until both eyes were at study endpoints.

PROCEDUREConventional Oxygen Management

Conventional oxygen arm with pulse oximetry targeted at 89% to 94% saturation.

Sponsors

National Center for Research Resources (NCRR)
CollaboratorNIH
National Eye Institute (NEI)
CollaboratorNIH
National Institute of Nursing Research (NINR)
CollaboratorNIH
Delta Gamma Sorority
CollaboratorUNKNOWN
Rhea and Raymond White
CollaboratorUNKNOWN
Research to Prevent Blindness
CollaboratorOTHER
NICHD Neonatal Research Network
Lead SponsorNETWORK

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
No minimum to 48 Hours
Healthy volunteers
No

Inclusion criteria

* Infants with prethreshold retinopathy of prematurity, confirmed by 2 certified ophthalmologic exams * Median pulse oxygen saturation \<94% in room air * Median pulse oxygen saturation can be kept safely \>96% on oxygen/ventilator

Exclusion criteria

* No fatal congenital anomaly or congenital eye anomaly

Design outcomes

Primary

MeasureTime frameDescription
Progression from moderate to severe ROP (prethreshold) to threshold ROP requiring peripheral ablative surgery3 months of ageProgressing from moderate ROP (prethreshold) to threshold ROP requiring peripheral ablative surgery

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026